Cyclacel Stock Executives

CYCC
 Stock
  

USD 0.81  0.03  3.57%   

Cyclacel Pharmaceuti employes about 12 people. The company is managed by 11 executives with total tenure of roughly 138 years, averaging almost 12.0 years of service per executive having 1.09 employees per reported executive. Analysis of Cyclacel Pharmaceuti management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Cyclacel Pharmaceuti future performance.
Continue to Trending Equities.
  
  Spiro Rombotis  CEO
CEO and President and Executive Director
  David UPrichard  Chairman
Independent Chairman of the Board
  Christopher Henney  Chairman
Independent Vice Chairman of the Board

Cyclacel Pharmaceuti Management Team Effectiveness

Cyclacel Pharmaceuti has return on total asset (ROA) of (38.07) % which means that it has lost $38.07 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (51.66) %, meaning that it created substantial loss on money invested by shareholders. Cyclacel Pharmaceuti management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Cyclacel Pharmaceuti Workforce Comparison

Cyclacel Pharmaceuti is rated third in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 322,827. Cyclacel Pharmaceuti adds roughly 12.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.

Cyclacel Pharmaceuti Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyclacel Pharmaceuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyclacel Pharmaceuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cyclacel Pharmaceuti insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Cyclacel Pharmaceuti Benchmark Summation

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Lowest value over a specified period line plots minimum value of Cyclacel Pharmaceuti price series.
.

Cyclacel Pharmaceuti Notable Stakeholders

A Cyclacel Pharmaceuti stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cyclacel Pharmaceuti often face trade-offs trying to please all of them. Cyclacel Pharmaceuti's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cyclacel Pharmaceuti's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Spiro Rombotis - CEO and President and Executive DirectorProfile
David UPrichard - Independent Chairman of the BoardProfile
Christopher Henney - Independent Vice Chairman of the BoardProfile
Judy Chiao - Vice President - Clinical Development and Regulatory AffairsProfile
Nicholas Bacopoulos - Independent DirectorProfile
Lloyd Sems - Independent DirectorProfile
Samuel Barker - DirectorProfile
Gregory Hradsky - Independent DirectorProfile
John Banham - Independent DirectorProfile
Robert Spiegel - Independent DirectorProfile
Paul McBarron - COO, CFO, Principal Accounting Officer, Executive VP of Fin. and Admin., Secretary and Executive DirectorProfile

About Cyclacel Pharmaceuti Management Performance

The success or failure of an entity such as Cyclacel Pharmaceuti often depends on how effective the management is. Cyclacel Pharmaceuti management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cyclacel management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cyclacel management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
The data published in Cyclacel Pharmaceuti's official financial statements usually reflect Cyclacel Pharmaceuti's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cyclacel Pharmaceuti. For example, before you start analyzing numbers published by Cyclacel accountants, it's critical to develop an understanding of what Cyclacel Pharmaceuti's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Cyclacel Pharmaceuti's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cyclacel Pharmaceuti's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cyclacel Pharmaceuti's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cyclacel Pharmaceuti. Please utilize our Beneish M Score to check the likelihood of Cyclacel Pharmaceuti's management to manipulate its earnings.

Cyclacel Pharmaceuti Workforce Analysis

Traditionally, organizations such as Cyclacel Pharmaceuti use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cyclacel Pharmaceuti within its industry.

Cyclacel Pharmaceuti Manpower Efficiency

Return on Cyclacel Pharmaceuti Manpower

Revenue Per Employee12.5 K
Revenue Per Executive13.6 K
Net Loss Per Employee1.6 M
Net Loss Per Executive1.7 M
Working Capital Per Employee1.6 M
Working Capital Per Executive1.7 M
Continue to Trending Equities. Note that the Cyclacel Pharmaceuti information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuti price analysis, check to measure Cyclacel Pharmaceuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuti is operating at the current time. Most of Cyclacel Pharmaceuti's value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cyclacel Pharmaceuti's price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuti to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Cyclacel Pharmaceuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuti. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
10.6 M
Return On Assets
(0.42) 
Return On Equity
(0.60) 
The market value of Cyclacel Pharmaceuti is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuti's value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuti's market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Cyclacel Pharmaceuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.